Millions of Medicaid beneficiaries have limited access to Type 2 diabetes medications that reduce the risk of cardiovascular disease, according to a study published April 22 in Annals of Internal Medicine.
An analysis of 50 state Medicaid plans and 273 nonelderly adult managed care organization plans associated with Medicaid examined the availability of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Both drug classes include medicines approved for both diabetes and cardiovascular disease.
In comparison to dipeptidyl peptidase-4 inhibitors, which are approved for diabetes, researchers found that 2.72 million beneficiaries have restricted availability of GLP-1s, 1.7 million of SGLT2is and 1.5 million of DPP4is.
These restrictions were most common among managed care organization plans, according to the study.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
